CD47 and neoplasm: MSF@CCM combines the biomimetic properties of CCM for immune evasion by mimicking “self” markers (e.g., CD47) and tumor targeting through homotypic cell recognition, achieving 2.0-fold higher tumor retention than non-camouflaged nanomedicine.